Skip to main content
. 2021 Aug 10;21:908. doi: 10.1186/s12885-021-08649-z

Fig. 5.

Fig. 5

The Kaplan–Meier curves for the progression-free survival rate of metastatic breast cancer patients stratified by the response on 18F-FLT-PET or 18F-FDG-PET after one or two cycles of chemotherapy. The metabolic responders on post-2c 18F-FDG-PET based on PERCIST showed a significantly higher survival rate than metabolic non-responders

HHS Vulnerability Disclosure